Formulary Watch |

All News - Page 8

Oral Postpartum Depression Drug Zurzuvae Launches
Oral Postpartum Depression Drug Zurzuvae Launches
Oral Postpartum Depression Drug Zurzuvae Launches
December 14, 2023
Zurzuvae has a list price of $15,900 for a 14-day course of treatment. No coverage information has been released.
Stepan Popov-stock.adobe.com
MAPS Submits NDA for Psychedelic Therapy for PTSD
MAPS Submits NDA for Psychedelic Therapy for PTSD
December 12, 2023
The application for midomafetamine is the first NDA submission for any psychedelic-assisted therapy.
ICER: Humira Among Drugs that had Unsupported Price Increases in 2022
ICER: Humira Among Drugs that had Unsupported Price Increases in 2022
ICER: Humira Among Drugs that had Unsupported Price Increases in 2022
December 11, 2023
Eight of 10 drugs reviewed by Institute for Clinical and Economic Review were not supported by clinical evidence.
Ezume Images-stock.adobe.com
FDA Approves Two Gene Therapies for Sickle Cell Disease
FDA Approves Two Gene Therapies for Sickle Cell Disease
December 8, 2023
The FDA has approved the gene therapies Lyfgenia and Casgevy to treat patients with sickle cell disease. Casgevy is the first FDA-approved gene therapy to use the CRISPR gene editing technology.
Drug Costs, Regulation are Top of Mind of Mind for Employers
Drug Costs, Regulation are Top of Mind of Mind for Employers
Drug Costs, Regulation are Top of Mind of Mind for Employers
December 8, 2023
IQVIA’s Michael Kleinrock and experts at RxBenefits reveal during webinar top pharmacy trends going into 2024.
freshidea-stock.adobe.com
Study Questions Whether the High Price of Ocrevus is Warranted
Study Questions Whether the High Price of Ocrevus is Warranted
December 6, 2023
Researchers suggest a head-to-head comparative effectiveness study of Ocrevus and Rituxan/biosimilars in patients with multiple sclerosis is needed for payers to negotiate prices for these therapies.
Express Scripts and Cigna Add Zepbound to Formularies
Express Scripts and Cigna Add Zepbound to Formularies
Express Scripts and Cigna Add Zepbound to Formularies
December 5, 2023
Zepbound, which was approved last month to treat obesity, is now available in U.S. pharmacies.
 SpeedShutter_stock.adobe.com
IQVIA: Drug Shortages are Growing
IQVIA: Drug Shortages are Growing
December 4, 2023
Shortages are growing because of disruption caused natural disasters and ingredient supply issues, as well as increased demand for certain drugs.
Trifonenko Ivan-stock.adobe.com
Younger People Are Looking to GLP-1 Drugs for Weight Loss
Younger People Are Looking to GLP-1 Drugs for Weight Loss
November 30, 2023
A new survey finds that more people are using semaglutide and other GLP-1 therapies to lose less than 15 pounds.
HHS: Opportunities to Reduce Medicare Part B Spending with Biosimilars Remain
HHS: Opportunities to Reduce Medicare Part B Spending with Biosimilars Remain
HHS: Opportunities to Reduce Medicare Part B Spending with Biosimilars Remain
November 30, 2023
Although biosimilars have already generated savings for Medicare Part B programs and beneficiaries, opportunities for substantial reductions in spending remain, according to a report from the HHS.
© 2024 MJH Life Sciences

All rights reserved.